Last update Oct. 30, 2023
Alefacept is a recombinant human fusion protein that binds to CD2 on memory T cells, preventing their activation and reducing their number. It is used in the treatment of moderate to severe chronic plaque psoriasis. Intramuscular administration one dose per week for 12 weeks.
At the time of the last update, we found no published data on its excretion in breast milk.
Its high molecular weight makes it unlikely to pass into breast milk.
Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tract and is not absorbed.
We do not have alternatives for Alefacept.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM